Skip to main content
. Author manuscript; available in PMC: 2013 May 14.
Published in final edited form as: J Rheumatol. 2011 Mar 16;38(6):1048–1054. doi: 10.3899/jrheum.100735

Table 1.

Conditional logistic regression of log-marker levels with active disease vs remission (n = 151). Results expressed as OR for active disease per unit-increase in log-marker level.

Marker Crude Association Adjusted for CRP Adjusted for PR3-ANCA Adjusted for All Markers
OR (95% CI) Std β OR (95% CI) Std β OR (95% CI) Std β OR (95% CI) Std β
sCD40L 4.72 (2.47, 9.03) 0.75 4.26 (2.22, 8.17) 0.70 3.08 (1.60, 5.96) 0.54 3.66 (1.38, 9.72) 0.62
CRP 1.54 (1.16, 2.04) 0.33 1.47 (1.04, 2.08) 0.30 1.06 (0.59, 1.90) 0.05
IL-6 1.04 (0.63, 1.71) 0.01 0.79 (0.45, 1.40) −0.07 0.64 (0.34, 1.19) −0.14 0.92 (0.23, 3.65) −0.02
IL-8 1.93 (1.33, 2.80) 0.33 1.68 (1.15, 2.47) 0.26 1.89 (1.22, 2.92) 0.32 3.19 (1.23, 8.28) 0.59
MCP-1 0.36 (0.22, 0.57) −0.46 0.23 (0.13, 0.42) −0.58 0.45 (0.27, 0.76) −0.35 0.13 (0.04, 0.51) −0.78
P-selectin 6.26 (2.78, 14.10) 0.82 5.26 (2.27, 12.19) 0.70 3.57 (1.52, 8.41) 0.57 2.54 (0.82, 7.84) 0.40
VEGF 2.13 (1.38, 3.29) 0.44 1.77 (1.13, 2.77) 0.33 2.05 (1.21, 3.46) 0.41 1.28 (0.46, 3.61) 0.14
PR3-ANCA 9.41 (4.03, 21.99) 1.01 11.86 (4.40, 31.95) 1.10 5.56 (1.49, 20.74) 0.75

Std β: standardized β estimate; sCD40L: soluble CD40 ligand; CRP: C-reactive protein; IL: interleukin; MCP-1: monocyte chemoattractant protein 1; VEGF: vascular endothelial growth factor; PR3-ANCA: antiproteinase 3 antineutrophil cytoplasmic antibody.